Synapse - Venkatraman Seshan

Search Within

Venkatraman Ennapadam Seshan

Results (373)

Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring

Journal Article

Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
Clinical Cancer Research (2022)

Fulltext@MSK | Save

Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence

Meeting Abstract

Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
Blood (2021)

Fulltext@MSK | Save

Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)

Meeting Abstract

Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
Blood (2021)

Fulltext@MSK | Save

Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)

Meeting Abstract

Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
Blood (2021)

Fulltext@MSK | Save

A prospective multicenter study of minimal residual disease assessment using a next-generation immunosequencing assay and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma

Meeting Abstract

Kumar, A.; Westin, J. R.; Schuster, S. J.; Nowakowski, G. S.; Lossos, I. S.; Copley, D.; Grieve, C.; Jacob, A. P.; Joseph, A.; Laraque, L.; more...
Blood (2021)

Fulltext@MSK | Save

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial

Journal Article

Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
The Lancet Haematology (2021)

Fulltext@MSK | Save

Validity of a method for identifying disease subtypes that are etiologically heterogeneous

Journal Article

Zabor, E. C.; Seshan, V. E.; Wang, S.; Begg, C. B.
Statistical Methods in Medical Research (2021)

Fulltext@MSK | Save

Ectopic activation of the miR-200c–EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy

Journal Article

Zhang, M.; Zhao, Z.; Pritykin, Y.; Hannum, M.; Scott, A. C.; Kuo, F.; Sanghvi, V.; Chan, T. A.; Seshan, V.; Wendel, H. G.; more...
Science Translational Medicine (2021)

Fulltext@MSK | Save

ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors

Journal Article

Portelinha, A.; Thompson, S.; Smith, R. A.; Da Silva Ferreira, M.; Asgari, Z.; Knezevic, A.; Seshan, V.; de Stanchina, E.; Gupta, S.; Denis, L.; more...
Cell Reports Medicine (2021)

Fulltext@MSK | Save

Clinical outcomes and the role of observation in early‐stage follicular lymphoma

Meeting Abstract

Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Kumar, A.; more...
Hematological Oncology (2021)

Fulltext@MSK | Save